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Aggregation of highly phosphorylated tau into aggregated forms such as filaments and
neurofibrillary tangles is one of the defining pathological hallmarks of Alzheimer’s dis-
ease and other tauopathies. Hence therapeutic strategies have focused on inhibition of
tau phosphorylation or disruption of aggregation. However, animal models imply that tau-
mediated dysfunction and toxicity do not require aggregation but instead are caused by
soluble hyper-phosphorylated tau. Over the years, our findings from a Drosophila model
of tauopathy have reinforced this. We have shown that highly phosphorylated wild-type
human tau causes behavioral deficits resulting from synaptic dysfunction, axonal transport
disruption, and cytoskeletal destabilization in vivo.These deficits are evident in the absence
of neuronal death or filament/tangle formation. Unsurprisingly, both pharmacological and
genetic inhibition of GSK-3β rescue these tau phenotypes. However, GSK-3β inhibition also
unexpectedly increases tau protein levels, and produces insoluble granular tau oligomers.
As well as underlining the growing consensus that tau toxicity is mediated by a highly
phosphorylated soluble tau species, our findings further show that not all insoluble tau
aggregates are toxic. Some tau aggregates, in particular tau oligomers, are non-toxic, and
may even be protective against tau toxicity in vivo.This has serious implications for emerg-
ing therapeutic strategies to dissolve tau aggregates, which might be ineffective or even
counter-productive. In light of this, it is imperative to identify the key toxic tau species
and to understand how it mediates dysfunction and degeneration so that the effective
disease-modifying therapies can be developed.
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INTRODUCTION
TAU PROTEIN IN ALZHEIMER’S DISEASE AND OTHER TAUOPATHIES
Deposits of insoluble tau within neurons are defining pathologi-
cal hallmarks in the group of neurodegenerative diseases known
as tauopathies. Tauopathies include Alzheimer’s disease (AD),
Fronto-temporal Dementia with Parkinsonism on chromosome-
17 (FTDP-17), Pick’s disease, Corticobasal Degeneration (CBD),
Progressive Supranuclear Palsy (PSP), and others (1). In all of these
conditions, tau becomes both abnormally hyper-phosphorylated
and deposited in insoluble aggregates [reviewed in Ref. (1, 2)].
These diseases differ in their clinical features, differentially-
affected neuronal populations, and the distinct forms taken by the
insoluble tau. Indeed, even within one disease state, the insoluble
tau may be found in many distinct morphological forms; some en
route to the final form of that disease’s tau deposits, and others
possibly on a different pathway.
In this review we will focus primarily on the forms of insoluble
tau observed in AD, since they have been more widely studied.
We will describe the different species of insoluble tau that have
been identified; briefly review the factors that might promote tau
aggregation; and then assess the evidence for and against the tox-
icity of each type of tau aggregate. Inevitably, this cannot be a
comprehensive account of the extensive literature on this subject
in the interests of space. Therefore we have selected papers which
we believe represent the balance of evidence for and against toxi-
city, with apologies to those whose work we have not included. In
this context we will use the term toxicity rather broadly, meaning
either neuronal death, or neuronal dysfunction without death.
PHYSIOLOGICAL AND PATHOLOGICAL SPECIES OF TAU
This section briefly describes the major forms that tau has been
shown to take in AD. These different species are treated in approx-
imate order of size, from smallest to largest (Table 1). However,
there is no intention to imply that each one goes on to form the
next in a clear pathway.
MONOMER
Monomers of tau are highly soluble proteins of 55–74 kDa in
size [depending upon splice variant and phosphorylation sta-
tus – (3)]. There are six splice variants which contain either three
or four microtubule-binding repeats, as well as either zero, one,
or two N-terminal domains. These isoforms are usually denoted
tau0N3R, tau1N3R, tau2N3R, tau0N4R, tau1N4R, and tau2N4R. They
usually acquire a predominantly random coil structure under
normal physiological conditions (4). Partially folded forms of
tau monomers have also been described which are distinct from
native tau monomers, and have a reduced level of random coil-
ing but an increased level of β-sheet structure (5). Interestingly,
such molecules are immediately positive for Thioflavin (which
binds β-sheet). Compact monomers have also been characterized
displaying intra-molecular disulfide bonds (6). Only the three iso-
forms of four-repeat tau can form these compact monomers, since
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Table 1 | Summary of the major forms of tau identified.
Species of tau Abnormally
phosphorylated?
Toxic?
Monomer Sometimes Probably only when aberrantly
phosphorylated
Dimer/trimer Sometimes Some types shown to be
sufficient for toxicity
Small soluble
oligomer
Sometimes Some types shown to be
sufficient for toxicity
Granular Tau oligomer Sometimes Not always
Filament Yes Might comprise of toxic tau,
yet filaments themselves are
probably neither necessary
nor sufficient for toxicity
Neurofibrillary tangle Yes Might comprise of toxic tau,
yet tangles themselves are
probably neither necessary
nor sufficient for toxicity
Ghost tangle Yes Unlikely
the second cysteine required for an intra-molecular interaction is
in the extra repeat domain.
DIMER/TRIMER
Dimers are composed of two tau monomers in anti-parallel ori-
entation linked by disulfide bonds. Tau dimers can be observed
by electron microscopy (EM) as rod-like particles 22–25 nm long,
which is similar in appearance to the monomers (7). Dimers can
form from any isoforms of tau. Within that, however, two dis-
tinctly different forms of dimers have been described (8). One
is cysteine-dependent and reducible; while in contrast the other
is cysteine-independent, non-reducible, and has inter-molecular
disulfide bridging at the microtubule-binding domain. Both forms
have been identified in vitro, and in tau transgenic (JNPL3) mice
(8). Preparing small oligomers from recombinant tau in vitro,
dimers have been reported with apparent sizes of 180 kDa (9)
and 130 kDa (10), as well as trimers with an apparent size of
120 kDa (11). In human tau transgenic mice, soluble tau species
of 140 kDa have been described (8, 12). Small soluble tau species
of approximately dimer and trimer size, and probably including
tau fragments, have also been isolated from synapses in AD brains
(13). It is unclear whether these variously reported dimers and
trimers are indeed different tau species or whether they represent
subtle variations of the same structure.
SMALL SOLUBLE OLIGOMER
Small soluble oligomers of tau of very many different sizes have
been described in vitro and in vivo. Often, however (perhaps
because of differences in post-translational modifications leading
to different apparent sizes on PAGE), it can be difficult to deter-
mine if small oligomers described by different groups represent
the same species or not. In one study, the soluble dimers described
above were shown in vitro to develop into small soluble oligomers
containing six to eight tau molecules (approximately 300–500 kDa
in size) (8). JNPL3 mice, which over-express human tau with the
P301L mutation (tau0N4R-P301L) and harbor neurofibrillary tan-
gles (NFTs), additionally have small tau oligomers which run at a
wide range of sizes by PAGE [Sahara et al. (8)].
INSOLUBLE GRANULAR TAU OLIGOMER
Granular tau oligomers (GTOs) are electron-dense granular or
globular aggregates of tau. They have been isolated from AD
brains, mostly at early and moderate Braak stages (14). GTOs are
composed of an average of 40 densely packed tau monomers. This
corresponds to a size of 1800 kDa, or 20–50 nm in diameter when
observed by EM or by atomic force microscopy (AFM) (15). It is
important to note that, on the scale of insoluble protein aggre-
gates generally, this is extremely small. Standard protocols for the
sedimentation of insoluble proteins, such as 100,000× g spin for
30–60 min [e.g., Ref. (16)], would fail to sediment GTOs which
would remain in suspension in the “soluble” fraction, despite
their demonstrable insolubility in SDS (15). Instead, sedimenta-
tion of GTOs requires a 200,000× g spin for 2 h (15). The same
authors developed a rigorous fractionation/purification protocol
for GTOs. They further characterized the GTOs as being positive
for MC1 and for Thioflavin, despite clearly being not filamentous
in any way. They conclude that GTOs have β-sheet structure, and
suggest that they may be composed of the partially folded form of
tau monomer (15).
FILAMENT
It is well known that tau is capable of polymerization into filamen-
tous forms. In AD, the predominant filaments are Paired Helical
Filaments (PHF) and Straight Filaments (SF). In other tauopathies
such as FTDP-17, however, there is variability in the morphology
of tau filaments depending upon the tau mutations and/or tau
isoforms involved. Here, filaments may take on other shapes such
as twisted ribbon-like and rope-like filaments (17). A straight fil-
ament strand is 10 nm wide, and thus PHFs display alternating
widths of 10 and 20 nm, with a half-periodicity of 80 nm (18, 19).
Tau filaments exhibit β-sheet structure (20) which forms through
the MT-binding repeat region (7, 21). Tau filaments from human
AD brain have been shown to contain all six tau isoforms (22),
although in vitro they can also be formed from single isoforms.
They can be considered an amyloid (23, 24).
PRETANGLE
The pretangle is a slightly confusing concept that historically may
have referred to a variety of species of tau, or even the status
of a neuron. Generally speaking, a pretangle neuron is one that
is positive for abnormal tau epitopes (misfolded and/or hyper-
phosphorylated), in some insoluble format large enough to be
visible by light microscopy, yet free from mature fibrils or tangles
by morphology. Bancher et al. (25) helpfully classified tangles into
four stages (0–3). In this system1, stage 0 tangles (later referred to
1For reference, stage 1 in this system is filamentous silver-stained tangles composed
primarily of PHF; stage 2 is a classic neurofibrillary tangle and stage 3 is a ghost
tangle (See “Neurofibrillary Tangle” and “Ghost Tangle”).
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by others as pretangles) are identified by cytoplasmic non-fibrillar
(granular or diffuse) tau immunoreactivity, visible at the light
microscope level. When viewed by EM, the labeled material was
found to consist of PHFs, SFs, and smaller granular electron-dense
material. Where pretangles were observed as granular via light
microscopy, this probably represents non-filamentous clumps of
PHFs, SFs, and the ultrastructural granules. Other researchers have
described immunoreactivity for certain abnormal AD-associated
tau epitopes in neurons containing no fibrils, and have deemed the
neurons so labeled to be at a pretangle stage [for example Alz50
(26), the 12E8 epitope S262/S356 (27,28),and T231 (27,29)]. Con-
fusingly, there are a number of conflicting reports in the literature
as to whether “pretangles” are silver-staining, thioflavin-positive,
and whether or not they contain β-sheet structure. It seems prob-
able that these discrepancies arise from (a) a heterogeneity of what
is meant by “pretangle” and (b) a sensitivity issue in regard to the
assays for β-sheet. Pretangles should surely be positive for mark-
ers of β-sheet, since even the earliest partially-folded monomer
(5) and certainly tau filaments (30) demonstrably contain β-sheet
structure.
OTHER LARGE NON-FIBRILLAR TAU AGGREGATES
There are other forms and morphologies of pathological insoluble
tau found in human brains which are large enough to be seen with
the light microscope, and may be filamentous, yet are non-fibrillar
in structure. Such aggregates include Hirano bodies, Pick bodies,
and argyrophilic grains.
Hirano bodies have been described in AD, Pick’s disease and
other tauopathy brains (31, 32). Hirano bodies are large intraneu-
ronal paracrystalline structures of 5–10µm in width by 10–30µm
in length, composed of 7 nm filament arrays (32). They contain
tau, other microtubule-associated proteins, actin, cofilin, other
actin-binding proteins, and a fragment of APP.
Pick bodies are the characteristic morphology assumed by tau
filaments in Pick’s disease, in which they accumulate in limbic
and cortical neurons. They are large structures that vary in size
in different neuronal types, but are approximately the size of the
nucleus. Pick bodies are formed of disorganized bundles of fila-
ments which comprise only the three 3-repeat isoforms of tau, in
contrast to the PHFs and SFs formed in AD which are made of all
six isoforms [reviewed in Ref. (33)].
Argyrophilic grains are found in Argyrophilic Grain disease,
where they accumulate in both neuronal processes and oligo-
dendrocytes (34). Argyrophilic grains are structures that may be
spherical, oval, comma-shaped, or spindle-shaped. As the name
suggests, they are readily detectable by conventional silver-staining
and light microscopy. The grains are much smaller than Hirano
bodies, Pick bodies, and NFTs at approximately 4–9µm in size.
Argyrophilic grains are comprised of four-repeat tau in 9–18 nm
SF and bundles of 25 nm smooth tubules. They never contain
PHFs and ribbon-like filaments (34–36).
NEUROFIBRILLARY TANGLE
Neurofibrillary tangles are the classic tangles first described by
Alzheimer in 1907. Classified by Bancher et al. (25) as stage 2 tan-
gles and often described as “flame-shaped,” they are large bundles
of fibers consisting of both PHFs and SFs which may fill the entire
neuronal cytoplasm. The fibers are silver-staining. Brief mention
should be made here also of neuropil threads, which are bundles
of SFs and PHFs occupying dendrites and largely displacing the
cytoskeleton (37).
GHOST TANGLE
Ghost tangles are the structures that remain when the neuron
within which the tangle formed has degenerated. They comprise
large extracellular bundles of loosely arranged tau filaments. Com-
pared to NFTs, ghost tangles stain more weakly for tau and more
strongly for ubiquitin (25). It is thought that ghost tangles have
undergone substantial proteolysis, and that thus the filaments are
comprised predominantly of tau fragments, again in contrast to
NFTs (38).
THE SEQUENCE OF EVENTS IN TAU AGGREGATION
There is some evidence to suggest that larger tau aggregates like
PHFs and NFTs evolve from the successive aggregation of smaller
tau species like monomers and soluble oligomers (Figure 1). One
missing link appears to be whether small oligomers can form
directly into GTOs in a linear pathway, or whether they represent
two different pathways from monomers to PHFs and NFTs.
MONOMER→DIMER
There is evidence from the kinetics of tau polymerization that,
once the partially folded conformation of the monomer has
formed (however that may be triggered), then the process from
monomers to dimers (and thence to oligomers) is energetically
favorable and proceeds spontaneously (5). For monomers to be
able to form dimers requires the PHF6 hexapeptide in the third
microtubule-binding repeat domain (8, 39). However, the com-
pact form of the tau monomer does not participate in this form
of aggregation (40).
FIGURE 1 | A putative sequence of events in tau aggregation into
neurofibrillary tangles (NFTs).
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DIMER→SMALL SOLUBLE OLIGOMER
The tau dimer, in particular the cysteine-independent, non-
reducible form (8), is thought to be an important intermediate
which is involved in controlling the rate of formation of larger
intermediates and fibrillization (6, 7, 41). In addition, more than
one group has demonstrated that in vitro generated tau dimers
aggregate to form larger tau oligomers (8, 9).
SMALL SOLUBLE OLIGOMER→GTO
We are not aware of any direct evidence that small oligomers
proceed to form GTOs. There is, however, evidence that tau
monomers in vitro can form GTOs (15), as well as that
both monomers and GTOs can form PHFs. However, whether
the sequence always proceeds from monomer→ dimer→ small
oligomer→GTO→ filament, or whether GTOs and other types
of tau oligomers can be on different pathways, is not clear. In gen-
eral, it is believed that when tau forms larger structures such as
filaments of differing morphology, the interactions between tau
molecules remain the same, and subunit packing follows the same
plan (40). On these grounds it is plausible that GTOs might be
part of the same pathway.
GTO→PHF
Increasing the concentration of GTOs in vitro causes them to
form filaments, whereas the constituent soluble tau does not.
On the basis of this, it is suggested that GTOs are precursors of
PHFs (15).
MONOMER/DIMER→PHF (POSSIBLY VIA THE OTHER INTERMEDIATES)
There is a wide variety of evidence showing that monomers can
polymerizes into PHF, but that does not address whether this is
via the oligomeric intermediates or not. Such evidence includes
the early in vitro demonstrations that tau at high concentrations
will self-assemble into PHFs (42–44), and evidence that dimers
are normally rate-limiting intermediates in this process in vitro
(4, 6). There followed from these studies a large body of work
delineating important details such as which motifs within tau are
required for fibrillization, in which monomeric tau clearly formed
into PHFs (39, 45–47). However, as in the early studies, whether
oligomers were formed on the way was not necessarily assessed
directly.
The mechanism for PHF formation requires two hexapeptide
motifs in the microtubule-binding region of tau. These are PHF6
[(306)VQIVYK(311)] and PHF6∗ [(275)VQIINK(281)]. Forma-
tion of PHFs involves these two motifs changing conformation
from random coil to β-sheet structure (24, 39). It should be
noted that mutant tau containing no cysteines is still able to form
PHFs in vitro, even though much more slowly than WT tau (40).
This means that cysteine-dependent (covalent) dimers are not a
requisite stage between monomer and PHF.
PHF→NFT
It is well established that NFTs in vivo are composed of PHFs and
SFs (25). Furthermore, there is also direct in vitro evidence that
filaments will spontaneously clump together into NFTs (48). Thus
it is highly likely that NFTs are formed by the accumulation of tau
filaments.
WHAT PROMOTES TAU AGGREGATION?
Little is known about what first triggers the initiation of tau aggre-
gation. It is known that normal monomers do not spontaneously
seed aggregation, and that some sort of trigger is needed (30, 49).
However, numerous factors have been identified that can promote
or increase tau aggregation, at least in vitro [reviewed in Ref. (50)].
Enzymatic cleavage of the tau monomer is one such factor.
Truncation of the tau protein at Glu391 (51, 52), truncation by
caspases at Asp421 (53), cleavage by thrombin (54), removal of the
C terminus of the protein (55, 56), or deamination at asparagine
or glutamine residues (57) have all been shown to promote tau
aggregation [Reviewed in Ref. (58)].
Local concentration of tau can be key. Tau at high concentra-
tions in vitro forms PHFs (42–44). Moreover, the transition of tau
from random coil to β-sheet is also known to be concentration
dependent (39), further supporting the idea that excessive local
accumulation of tau may promote its aggregation (especially if
other pro-aggregating factors – such as those discussed below – are
also in the near vicinity).
Controversially, tau phosphorylation has been postulated to
both stimulate and repress its subsequent aggregation into fila-
ments. Circumstantial evidence for stimulation includes the sem-
inal fact that filamentous tau is highly hyper-phosphorylated (59)
at many sites. More direct but in vitro evidence shows that tau
phosphorylated at AD sites polymerizes more readily into tan-
gles of PHF/SF; dephosphorylation abolishes tau’s self-assembly;
and hyperphosphorylation of recombinant tau by brain kinases
induces its self-assembly into tangles of PHF/SF (60, 61). In a
cellular model, it has been shown that all three kinases GSK-3β,
MEKK, and JNK3 are required for tau aggregation (62). Phospho-
rylation of tau specifically at Thr231, Ser396, Ser422, and Ser404
promotes self-aggregation of tau into filaments (55, 63, 64). In vivo,
overexpression of the kinases GSK-3β or Cdk5 can promote tau
aggregation (65, 66). On the other hand, in vitro studies have
shown that tau phosphorylation is not necessary to drive tau into
PHFs (41, 67). On the contrary, phosphorylation of KXGS motifs
in the repeat region inhibits tau aggregation in vitro (54, 68).
Furthermore, more recently emerging data showing that tau aggre-
gates made up of recombinant non-phosphorylated tau can “seed”
further tau aggregation in cells (discussed below) also supports the
idea that phosphorylation is not required to promote aggregation
(69, 70). However, it is not yet known whether phosphorylated tau
would seed and promote aggregation at a different rate.
Some of the missense and deletion mutations found in tau in
cases of fronto-temporal dementia (FTDP-17), when expressed in
models, display enhanced aggregation compared to normal tau.
In vitro PHF formation is faster for recombinant tau harboring
one of various such mutations. Human tau with each one of the
point mutations G272V, N279K, V337M, or R406W shows signif-
icantly faster in vitro PHF formation than WT full-length human
tau, while the ∆K280 and P301L mutants form PHFs at dramat-
ically greater speeds (46). This phenomenon has been confirmed
in vivo: mice expressing mutant human tauP301L develop pathol-
ogy more readily than those expressing WT human tau, both on
0N4R and 2N4R tau backgrounds (71–73).
Many polyanionic cofactors of all kinds can promote PHF
assembly. These include glycosaminoglycans (GAGs) such as
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heparin and neuroparin (40, 74, 75); sulphoglycosaminoglycans
(sGAGs) like keratins or chondroitin sulfates (76), RNA (41);
polyglutamic acid (30, 41, 74); fatty acids such as arachadonic
acid (77, 78) and alkyl sulfate detergents (79).
Other factors which may promote tau aggregation include tis-
sue transglutaminase (80), Congo red (81), ferritin (82), H2O2 in
the presence of iron (Fenton’s reaction) (83), and quinones (84).
Despite this wealth of data over many years regarding factors
that promote aggregation, questions still remain about what initi-
ates tau aggregation in vivo in health and disease. However, once
tau aggregation has been initiated, it is believed to promote fur-
ther“prion”-like“seeding”and propagation of tau aggregation and
pathology (85). This was first demonstrated in vivo where stereo-
taxic injections of brain homogenate containing tau aggregates led
to induction and propagation of tau aggregation in tau transgenic
mice (85). Supportive data also emerged from studies in cell cul-
ture showing that incubation of tau-expressing cells with fibrils
of recombinant tau leads to induction of tau aggregation in the
recipient cells (69, 70).
ARE NEUROFIBRILLARY TANGLES TOXIC?
NFTs: EVIDENCE FOR TOXICITY
The evidence that associates NFTs with neuronal dysfunction
and neurodegeneration is largely correlative in nature. Studies of
human post-mortem brains initially implicated NFTs in toxic-
ity by showing a strong spatial and temporal correlation between
NFTs and severity of dementia, and between NFTs and neurode-
generation or neuronal death (86–92). Some tau transgenic mouse
models display neuron loss in the same timeframe and/or location
as NFT formation. For example, expression of tauP301L under the
thy1.2 promoter causes neuronal apoptosis at the same age as fil-
aments and NFTs (93); while tauP301L under the prion promoter
causes NFTs in spinal cord, brainstem, and pretangles in cortex,
at the same time as loss of motor neurons (71). Furthermore, in
tau mouse models, there is a correlation between reduction of
NFT and improvement in cognition (94). The limitation of these
correlative studies between reduced NFTs and reduced impair-
ments is that, in many cases, other smaller tau species may be
reduced also. This leaves open the question of whether it is the
reduction of the NFTs or the smaller species which has been
beneficial.
More direct evidence in favor of NFT toxicity comes from
mice conditionally expressing human tau fragments harboring
pro-aggregation or anti-aggregation mutations (95, 96). Pro-
aggregation mice develop PHFs, “pretangles,” and NFTs early;
followed by synaptic and neuronal loss. In constrast, mice express-
ing the same tau molecule but with the anti-aggregation mutation
never develop aggregates or neuronal pathology. This was verified
in aC. elegans model of tauopathy which went further to show that
treatment with anti-aggregation inhibitors protected against tau-
mediated toxicity (97). This suggests that tau aggregation in the
form of PHFs or larger has been the cause of cell death. Moreover,
when expression of human tau is suppressed, mice are rescued
from toxicity in terms of both cell death and cognition. This rep-
resents very strong evidence in favor or PHFs and/or NFTs as the
toxic species. These conclusions were difficult to reconcile with a
body of evidence detailed below proving that PHFs and NFTs are
neither necessary nor sufficient for toxicity. However, the authors
subsequently showed that in the animals expressing pro-aggregant
tau, toxicity might in fact be mediated by a species of tau smaller
than PHFs and NFTs (98, 99).
NFTs: EVIDENCE AGAINST TOXICITY
There is now strong evidence from a number of models that NFTs
are not required for tau-induced neuronal dysfunction and toxi-
city. In most Drosophila models of tauopathy, neuronal NFTs are
usually not formed at all, despite clear neurodegeneration, and
functional phenotypes (100–104). In some mouse models where
NFTs do form, cognitive/behavioral impairments and cell death
can be demonstrated earlier in the time course of the disease prior
to NFT formation (105). In a different mouse model [PrP44: the
shortest human tau isoform (tau0N3R) under the prion promoter]
the formation of tau filaments coincides in the time course of the
disease with phenotypes such as neurodegeneration and motor
deficits, while NFTs form later (106, 107).
There is also compelling evidence that NFTs are not suffi-
cient for toxicity, from mice that conditionally express human tau
(tau0N4R-P301L). These mice display age-dependent development
of NFTs, neuronal loss, and progressive motor deficits. When tau
expression is switched off after the onset of memory impairments
and NFT formation, memory improves and cell loss is stabilized,
yet NFTs remain (108, 109). Furthermore, when tau is turned off
at a timepoint when there are pretangles but no NFTs yet, the
pretangles stay stable. This indicates that they also are insuffi-
cient for toxicity. This is corroborated in a different study using
the same mice, in which a successful treatment reduced motor
deficits despite failing to reduce NFTs (110). Furthermore, tangle-
bearing neurons in this model were shown to be just as active
in a functional hippocampal circuit as non-tangle bearing neu-
rons (as evidenced by expression of the immediate early gene Arc
in response to environmental cues) (111). Further investigations
of the mouse conditionally expressing pro- and anti-aggregant
form of tau, mentioned in the preceding section, also supports
this view. The pro-aggregation mice develop learning and mem-
ory deficits from which they recover after tau expression is turned
off (98). However, it transpires that after an extended period of
tau suppression, NFTs still remain, as in the tau0N4R-P301L mice.
This implies that it is a smaller species of tau (soluble or insoluble)
which has decreased in correlation with behavioral improvement
in these studies (98).
In the light of such evidence, it has been suggested that forma-
tion of NFTs is a protective response that ultimately fails (58). This
review describes a scenario in which caspases, having become acti-
vated because the cell contains toxic tau and is thus under stress,
cleave the tau making it more fibrillogenic. Cleavage is unlikely to
be the only trigger, since the initial steps of aggregation can involve
primarily full-length tau isoforms (5, 112). Either way, the idea is
that once tau aggregates seed, they can sequester toxic tau and thus
delay cell death. However, the trade-off is that axonal transport is
compromised and cellular protein degradation pathways become
clogged, and thus the neuron gradually becomes dysfunctional
(58). This is supported by evidence that NFT-bearing neurons
appear to survive for decades (113) and maintain markers of nor-
mal gene expression (111), and may be in fact be longer lived than
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those neurons without NFTs in the AD brain that would have died
at earlier time-points and hence were not evident at post-mortem.
In conclusion, despite NFTs being a vital historical clue to the
involvement of tau in neurodegenerative disease, a wide variety
of strong evidence now exists that NFTs themselves are nei-
ther necessary nor sufficient to cause tau-induced toxicity and
dysfunction.
ARE TAU FILAMENTS TOXIC?
Some of the evidence regarding NFTs is also applicable as indirect
evidence about tau filament toxicity. That is, some of the evi-
dence in favor of large aggregates being toxic could really apply to
either NFTs or PHFs/SFs or both. Further, the evidence that NFTs
are not toxic naturally casts suspicion onto smaller pathological
species such as filaments. However, direct evidence for PHFs as the
primary toxic species, rather than something smaller, is sparse.
FILAMENTS: EVIDENCE FOR TOXICITY
As with the evidence in favor of NFT toxicity described above,
much of the evidence that implicates filaments as a toxic species of
tau is correlative in nature. For example, in some mouse models
of tauopathy, filaments coincide in the time course of the disease
with phenotypes such as neurodegeneration and motor deficits
(106), while NFTs form later (107). Similar results were seen in
one Drosophila model of tauopathy in which tau filament forma-
tion was reported (114). Furthermore, mutations in tau which are
responsible for FTDP-17 also promote faster tau filament forma-
tion (46), thus circumstantially implicating tau filaments in the
disease process.
An immunotherapy study targeting tau in a mouse model pro-
vided some more direct evidence in favor of PHF toxicity. In this
study, immunization of JNPL3 mice (with a short phosphorylated
tau fragment) served to reduce tau aggregation (into PHFs or
larger aggregates) and the associated behavioral phenotypes, but
failed to reduce smaller species of tau. This suggests that that PHFs
or larger tau aggregates are the toxic species in this model (115).
In another study, tau filaments but not monomers (at physiolog-
ical concentrations) were shown to selectively impair anterograde
transport in isolated squid axoplasm (116, 117).
FILAMENTS: EVIDENCE AGAINST TOXICITY
As with the NFT situation, some animal models have impairment
but no filaments, or at least not until later in the disease pro-
gression. For example, Drosophila (100–104) and C. elegans (118)
expressing human tau display behavioral phenotypes indicative of
neuronal dysfunction and toxicity without forming tau filaments
or larger aggregates. Even in mice, in the transgenic tau model
expressing the longest human tau isoform (tau2N4R), brains con-
tain some form of insoluble tau but nothing as big as PHFs (or
NFTs), while the animals display a motor impairment (119). Such
evidence indicates that filaments are not necessary for tau-induced
toxicity.
There is also evidence that filaments are not sufficient for toxi-
city, since they continue to form in the conditional tau mice men-
tioned earlier, in which transgenic tau expression has been turned
off and deficits thereby rescued (108). In another mouse model,
Andorfer et al. showed that, while there was widespread neurode-
generation, the PHF-containing neurons appeared “healthy” in
terms of nuclear morphology, suggesting that the polymerized
protein was probably neuroprotective (105). In an in vivo lam-
prey model (120), administration of a benzothiazole derivative
drug (purported to break up tau filaments) successfully improved
tau-induced phenotype, but apparently did so without actually
breaking up the tau filaments. This provides further evidence that
filaments are not sufficient for toxicity. In vitro, polymerization
of hyper-phosphorylated tau into PHFs abolishes its toxic activity
to sequester other MAPs (121). Unlike the soluble form of hyper-
phosphorylated tau, the filamentous form of tau does not bind
MAPs and does not disrupt microtubules in vitro (121).
In an inducible cell line, the repeat domain of wild-type tau was
non-toxic, whereas a similar construct harboring a point mutation
that induced aggregate formation (eventually PHFs) caused cell
death (54). Crucially, however, increased cell death was observed
before PHF formation in the aggregate-prone mutant, demon-
strating that PHFs were not necessary for toxicity, and that in fact
a smaller form of aggregate was the toxic species.
While the in vivo evidence is not quite as extensive as for NFTs,
one can also conclude that tau filaments are neither necessary
nor sufficient for tau-induced toxicity, and that something smaller
than filaments is the most toxic form of tau.
SPECIES OF TAU FOUND IN FILAMENTS
When the insoluble protein fraction from brains of AD patients or
animal models, containing any tau filaments or larger tau aggre-
gates, is solublized using urea or formic acid, the tau species which
were building blocks of these large insoluble aggregates can be
identified. These species include monomers of 55, 60, 64, and
68 kDa in size (67), and a 170-kDa species. The 64 and 170 kDa
species in particular have been implicated in toxicity. The 64-kDa
species represents a hyper-phosphorylated monomer. It is found in
brains of the tau0N4R-P301L transgenic mouse (122), and increases
with age in the insoluble fraction at the expense of the 55-kDa
monomer (which is found in both soluble and insoluble fractions).
In the same study that showed NFTs were not necessary for
toxicity [because they did not decrease in successfully treated
tau mice – (110)], the successfully treated mice displayed a sig-
nificant reduction in 64 kDa tau from the high-speed insoluble
fraction. Confusingly, subsequent commentators have described
this species as “soluble aggregated tau” [e.g., Ref. (123)]. However,
this 64 kDa species is always a component of an aggregate that
sediments at 150,000× g, which is therefore bigger than a GTO.
Another study in a conditional mouse model found that three dis-
tinct tau species correlated with neuronal dysfunction (12). Two
of these species were in a sarkosyl-insoluble fraction (from which
NFTs had been previously cleared) which must represent GTOs
or filaments: a 64-kDa hyper-phosphorylated monomer and a
170-kDa hyper-phosphorylated oligomer. The third species was
a 140-kDa oligomer from the soluble fraction. All of these species
arose early in the disease progression, and increased with increas-
ing learning and memory deficits. Conversely, all three decreased
upon suppression of transgenic tau expression and recovery from
neuronal dysfunction. These results clearly implicate one or more
of the three species in toxicity; however, it is not clear whether
the culprit is the soluble or insoluble components or both. The
same 64 kDa species has also been described in a sarkosyl-insoluble
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fraction from transgenic tau0N4R-301L mice that represents SFs and
NFTs (71, 108). It is not toxic in this circumstance because it con-
tinues to increase after tau expression has been turned off and
animals are recovering (108).
In summary, these two species of tau, a hyper-phosphorylated
64 kDa monomer and a 170-kDa oligomer, have frequently been
demonstrated as components of an insoluble filament fraction.
There is some evidence, although not conclusive, that these species
may be associated with toxicity.
ARE (INSOLUBLE) GRANULAR TAU OLIGOMERS TOXIC?
Part of the difficulty in acquiring evidence about GTOs from the
existing literature is that, as mentioned earlier, in standard insol-
uble protein fractionation protocols any GTOs in the sample will
be lost. Even though fully insoluble, they are too small to sedi-
ment with a standard “high-speed insoluble” fraction (15). They
remain in suspension in the “soluble” fraction; and yet as they are
around 1800 kDa in size and not readily reducible without 8 M
urea, they will not enter a standard PAGE resolving gel and be
detected (Cowan, unpublished observation). Therefore when one
reads, for example, studies in tau mouse models showing small
oligomers and PHFs and drawing conclusions about toxicity, one
cannot usually conclude anything about the presence or absence,
toxicity or otherwise, of GTOs.
GTOs: EVIDENCE FOR TOXICITY
In the years following the identification of GTOs, when evidence
was beginning to accumulate that PHFs and NFTs might not
be toxic, some evidence remained that some insoluble form of
tau must be toxic. There was speculation in reviews that insol-
uble oligomers of tau, perhaps GTOs, might be the most toxic
species. However, there is no direct evidence for this. Clues that
GTOs might be associated with toxicity come from studies show-
ing that numbers of GTOs increase with progression of AD, that
fewer GTOs are observed at Braak stage 0 than at stage 1, and
that their peak precedes that of NFTs (14). GTOs are gener-
ally believed to consist of toxic phosphorylated species of tau
because phosphorylated tau levels are high in the AD brain at
the time-points when GTOs are abundant. Such clues have led to
the suggestion that reducing GTOs may prove to be a promising
therapeutic strategy; however, the authors of these publications
acknowledge that the effect of GTOs on neuronal vulnerability is
unknown.
There is also evidence that an insoluble oligomer(s) of some
sort is probably the culprit, without clear evidence that it is GTOs.
For example, in the study mentioned as evidence against PHF tox-
icity in an inducible cell line (54), the soluble tau construct was
not toxic, whereas the aggregate-prone mutant tau species caused
cell death prior to PHF formation. This therefore represents evi-
dence against both soluble tau toxicity and PHF toxicity, but rather
implicates some intermediate species. Similarly, in another study,
very small insoluble tau oligomers (of up to a few hundred kDa)
were isolated from synaptosomes derived from AD brains and were
associated with impaired ubiquitin proteasome function (124). If
any GTOs had been present in this preparation, they might not
have been observed with the protocols used. Clearly small insolu-
ble tau oligomers exist and are associated with toxicity but whether
they can be classified as GTOs or indeed their precursors is not
clear.
GTOs: EVIDENCE AGAINST TOXICITY
We have recently observed, in a Drosophila model of tauopathy,
the formation of GTOs which are non-toxic (125) When flies
express human tau0N3R in neurons they exhibit a clear behav-
ioral phenotype, but no insoluble tau. However, upon pharma-
cological or genetic manipulations which inhibit GSK-3β, the
phenotype is rescued and GTOs are produced. We demonstrate
that these GTOs produced in flies are the same size as those iso-
lated from human brain and comprise of non-phosphorylated
full-length tau monomers. Like us, another group has also
demonstrated the formation of large insoluble tau oligomers in
Drosophila, in conditions associated with rescue of tau-mediated
toxicity (126). They showed that rescue of human tau0N4R or
tau0N4R-R406W induced neurodegeneration and behavioral deficits
by co-expression of Nicotinamide mononucleotide adenylyltrans-
ferase (NMNAT) also led to increased formation of insoluble tau
oligomers. However whether these insoluble tau oligomers were
the same as the GTOs that we described in our model is not clear.
Nonetheless, both our studies collectively imply that tau aggre-
gation can correlate with rescue from tau-induced phenotype.
However, whether this is because of sequestration of smaller toxic
tau species, or the presence of non-phosphorylated tau in the con-
ditions in which the GTOs form, or something else about their
structure is not clear.
Overall, the pathological significance of GTOs has yet to be fully
understood. It is possible that different GTOs form in different cir-
cumstances and the phosphorylated status of their constituent tau
proteins and/or the extent of β-sheet structure may play a role in
determining their toxicity.
ARE SOLUBLE (MONOMERIC OR OLIGOMERIC) TAU SPECIES
TOXIC?
As has already been alluded to, there are numerous species of
tau that are soluble, and it seems probable that they possess
very different properties. Just considering monomers, there is
clearly a multiplicity of species: the three major conformations
described (regular, compact, and partially folded); the six splice
variants; and of course the array of phosphorylation combina-
tions, both demonstrated and possible, which have been barely
touched upon here. Then there are at least two conformations of
dimer (cysteine-dependent and independent), as well as trimers,
and small oligomers of various sizes and phosphorylation states,
as described earlier. We would speculate that there are probably
many variations of soluble oligomeric tau species occurring in
nature in the brain that have not yet been specifically described.
Further, some of the evidence regarding the toxicity or other-
wise of soluble tau cannot (or did not) differentiate between these
species.
SOLUBLE TAU: EVIDENCE FOR TOXICITY
There are many examples of studies conducted in vivo and in vitro
showing that soluble tau is sufficient to cause dysfunction and
toxicity. To give a few examples, pseudophosphorylated tau causes
cell death when virally expressed in hippocampal slices, with-
out becoming SDS-insoluble (127). Soluble tau monomer applied
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extracellularly to cells in culture causes intracellular calcium
increase and cell death (128, 129). Additionally, some tauopathy
models in Drosophila (100–102, 130) exhibit significant neuronal
dysfunction and degeneration and yet contain no insoluble tau
providing strong evidence that soluble tau is sufficient to cause
dysfunction and toxicity. Similar evidence exists in mouse mod-
els: for example, mice expressing WT tau2N4R under the CamK-II
promoter (131) as well as those expressing mutant tauN279K (132)
both display learning defects but no NFTs or insoluble tau and no
cell death. However, these mouse studies are subject to the caveat
discussed in Section “Are (Insoluble) Granular Tau Oligomers
(GTOs) Toxic?” that if there were any GTOs present they would
not have been detected by the protocols used. Therefore, strictly
speaking, we feel that the conclusion from such studies is: either
soluble tau or small insoluble tau oligomers are sufficient for
toxicity.
Further evidence supporting soluble tau toxicity comes from
many studies showing rescue of tau-mediated phenotypes after
suppression of tau expression which leads to reductions in solu-
ble tau but persistence of tangle pathology (58, 108, 111, 133).
In one such study, transgenic tauP301L mice were treated with
methylene blue at a dose sufficient to rescue their memory deficit,
and reduce total and soluble tau without affecting insoluble tau
aggregates (134). This study went one step further in showing
that the reduction of soluble tau is required for the rescue of
phenotype.
Whether the toxic soluble species of tau is monomeric or
oligomeric (or both) in these studies is not always clear. There
is a convincing body of evidence showing that certain specific
dimers, trimers, and other very small soluble oligomers are suf-
ficient to cause toxicity both in vitro and in vivo. Patterson et al.
(135) show that the 180-kDa dimers that they produced in vitro
can suppress fast axonal transport in a squid axoplasm model.
The 120-kDa trimers produced by Lasagna-Reeves et al. have been
shown to be toxic in vitro (11) and in vivo (136). These trimers
cause significantly more cell death than tau monomers or filaments
when applied to SH-SY5Y cells in culture (11). Intra-hippocampal
injections of trimers cause significant loss of synapses and neurons
resulting in memory deficits, whereas injections of tau monomers
or fibrils do not (136). Overall, these findings show that dimers
and trimers of tau can be toxic.
Tau species of this size range have also been demonstrated
in vivo, indicating that they are physiologically relevant. Both the
Kayed and the Binder laboratories have used the oligomers that
they made in vitro to raise oligomer-specific anti-tau antibod-
ies, TOC-1 (9) and T22 (137), which they demonstrate recog-
nize tau in situ in the post-mortem AD brain. Both oligomer-
specific antibodies react with “pretangles” in early Braak stages,
and co-localized with some disease-associated phospho-tau epi-
topes.
Small soluble oligomers also arise in many transgenic tau ani-
mal models in a context that implicates them in toxicity. For
example, transgenic Drosophila expressing either human tau0N4R
or tau0N4R-S406W in brain display soluble tau oligomers of 150–
250 kDa in size (114, 126) and in both studies oligomer formation
was associated with degeneration. Berger et al. (12) and Sahara
et al. (8) independently identified small soluble tau oligomers
of approximately 140 kDa (believed to be dimers) in brain
homogenates of tau0N4R-P301L transgenic mice. The oligomers
detected by Berger et al. (12) (in the inducible tau0N4R-P301L
mice) appeared at very early stages of disease when memory
deficits were evident in the absence of tangle formation or neu-
ronal loss. Either this 140 kDa soluble species and/or the two
small insoluble species of tau discussed in Section “Species of
Tau Found in Filaments” are implicated in causing toxicity in this
model.
Like the oligomers identified by the Binder and Kayed labora-
tories described above, the 140-kDa oligomers identified by Berger
et al. (12) in tau transgenic mice are also detectable in the brains
of AD and FTDP-17 patients. It is not clear whether all of these
oligomers are one and the same tau multimer or whether they rep-
resent tau oligomers at different stages of maturation during the
disease process. In addition, it has not been determined whether
aggregation into larger oligomers alters the toxicity of the small
tau oligomers.
SOLUBLE TAU: EVIDENCE AGAINST TOXICITY
Evidently, not all soluble phosphorylated tau can be toxic. Soluble
tau of many species is obviously found physiologically in healthy
individuals. One specific example of a soluble species known to be
non-toxic is the compact monomer with intra-molecular disulfide
bonds, which appears to be a species that is relatively protective
and, notably, does not go on to form larger aggregates (40).
In the tau immunization study mentioned earlier as evidence
in favor of PHF toxicity (115), it was found that immunization
causes reduced aggregation of tau into PHFs or larger aggregates,
and was associated with a reduced behavioral phenotype. How-
ever, this also causes an increase of PHF-1 immunoreactivity in
the “high-speed soluble” fraction, which in this case would repre-
sent any species of GTO size or smaller. This suggests not only that
PHFs might be toxic, but also that the soluble species present were
not sufficient for toxicity (115).
The inducible pro-aggregation and anti-aggregation mutants
of the tau repeat regions created by the Mandelkow laboratory
argue against toxicity of soluble tau. In both the cell lines [the study
mentioned as evidence against PHF toxicity: (54)], and in the mice
(95, 98), the common theme was that the anti-aggregation mutant,
which would always be a soluble form of tau, was never toxic. The
mouse lines provide some additional correlative evidence against
toxicity of any form of tau smaller than PHFs, in that the levels of
“soluble” tau were constant between the pro-aggregation mouse,
which experienced neurotoxicity, and the anti-aggregation mouse,
which did not.
Clearly, physiological tau is soluble and non-toxic. However,
under pathological conditions tau may undergo changes that
render it toxic, even though it may remain soluble.
DISTINGUISHING BETWEEN SMALL (SOLUBLE) TAU OLIGOMERS AND
TAU MONOMERS
In the above paragraphs, a general trend is that the evidence for sol-
uble tau toxicity centers on some reasonably well-defined dimers
and trimers which are demonstrably sufficient for toxicity; whereas
the evidence against either has not distinguished between the myr-
iad species, or has only said that one particular type of soluble tau
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is not toxic. In that sense, the evidence against is not conclusive.
While the specific data cited in favor of dimer and trimer toxicity
is compelling, we still know very little about the properties (or
indeed existence) of all the other soluble forms.
CONCLUSION
In conclusion, there is a body of evidence demonstrating that small
soluble tau oligomers are the most toxic form of tau. Filamentous
and fibrillar tau is neither necessary nor sufficient for tau-induced
toxicity, and may very well represent a neuroprotective strategy.
Such ideas are not new, and a number of reviews over the past few
years have drawn the same conclusions (138–140). Nevertheless,
this conclusion is still not broadly accepted. Even if it were to be
accepted, many questions remain. We still have little idea which of
the multiplicity of soluble tau species is the culprit or culprits: is
it monomers, dimers or trimers or all three, and in which confor-
mation(s) and phosphorylation state(s)? Also, we have incomplete
information about the sequence of events on the pathway(s) of tau
aggregation (Figure 2). Especially, where do GTOs fit in? Are they
made gradually from increasing sizes of smaller oligomers? Or do
they have a different conformation that makes them so compact
and insoluble? Can they really go on to form PHFs in vivo? Such
questions are important for informing the strategies to be imple-
mented when developing treatments for AD and tauopathies. We
do not yet know which species of tau would represent the best tar-
get for tau-based therapies. If a certain specific set of small soluble
tau oligomers are toxic, while insoluble GTOs and larger insoluble
tau species are not, then perhaps strategies aimed at breaking up
large insoluble tau aggregates might prove ineffective. Especially if
it transpires that GTOs are not only non-toxic but on an alterna-
tive pathway to PHFs, then perhaps encouraging GTO formation
might even turn out to be a valid approach. Alternatively, it might
not be size and solubility alone of the tau species that are the
FIGURE 2 | Cartoon of remaining questions.
key toxicity-determining factors: levels of β-sheet structure and
phosphorylation at certain sites may also be influential.
There is a precedent from other proteinopathies for a small sol-
uble species being the most toxic, while the smallest insoluble form
is relatively protective. This has been demonstrated for huntingtin
protein in Hungtington’s disease (141, 142), alpha-synuclein in
Parkinson’s disease (143), and amyloid beta in AD (144): however,
evidence for this phenomenon in the case of tau aggregation is
only beginning to emerge now.
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